Baird Medical Investment Holdings Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Baird Medical Investment
Surgical & Medical Instruments & Apparatus, SIC 3841
Baird Medical develops, manufactures, and commercializes proprietary microwave ablation medical devices focused primarily on thyroid diseases and tumor treatments. Its core products include microwave ablation therapeutic systems and single-use long and fine ablation needles designed for minimally invasive procedures. In addition to proprietary ablation technology, the business distributes third-party medical supplies, including ventilators, catheters, surgical tables, and disposable gloves. The company sells its medical apparatus to healthcare institutions, medical device distributors, and hospital deliverers.
Headquartered in Guangzhou, China, the company conducts its business primarily within the People's Republic of China. Its customer footprint encompasses 614 hospitals, including 329 Grade III medical facilities, across 24 Chinese provinces, municipalities, and autonomous regions. The enterprise operates through partnerships with 119 distributors and 11 delivery partners, supported by internal production and quality control personnel. Internationally, its therapeutic apparatus and needles have received regulatory clearance for soft tissue ablation in the United States and Indonesia.
Summary of the business section of Baird Medical Investment's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Baird Medical Investment Holdings Ltd
- Founded
- 2012
- Headquarters
- Sheung Wan, Hong Kong
- Address
- 18/F, Ovest, 77 Wing Lok Street
- Phone
- 86 159 1316 5120
- Website
- bairdmed.com
- Employees
- 146, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- Guangdong Prouden CPAs GP, Guangzhou, China
Stock & identifiers
- Ticker
- BDMD
- Other tickers
- BDMDW
- Exchange
- Nasdaq
- Shares outstanding
- 41M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-1.25 reverse, Apr 24, 2026
- SEC CIK
- 1982444
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rongjian Lu | Chief Technical Officer | – |
| Jie Clara Li | Acting Chief Financial Officer | – |
| Lijian Xu | Director | 25,000 |
| Quan Qiu | Director | – |
| Gabrielle Bilciu-Wolfson | Director | 20,000 |
| Wei Hou | Director | 91,545 |
| Joseph Douglas Ragan III | Director | 57,180 |
| Haimei Wu | Director | 18,195,281 |
Employees
Headcount reported in annual reports
“We had a total of 146 employees as of December 31, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2025 | Late filing | Notification of late filing |
| Oct 1, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 21, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |